Prof. Dr. Dag ÅarslandProf. Dr. Dag Åarsland is a physician and professor of Old Age Psychiatry at King’s College London, where he also serves as the Director of the Center for Healthy Brain Aging. He coordinates the IHI project PREDICTOM, which focuses on identifying biosignatures for the early and accurate diagnosis of Alzheimer’s Disease (AD) and personalized preventive interventions.
of. Dr. Miia KivipeltoProf. Dr. Miia Kivipelto is a physician and professor of Clinical Geriatrics at the Karolinska Institute in Stockholm. She coordinates the IHI project AD-RIDDLE, aimed at generating real-world evidence for the clinical implementation of precision diagnostics, interventions, and therapies. Miia is also the initiator of the global FINGERS program, which seeks to identify risk factors for neurodegenerative diseases.
rof. Dr. Linus JönssonProf. Dr. Linus Jönsson is a professor of Health Economics at the Karolinska Institute, where he coordinates the IHI project PROMINENT. This project leverages digital tools and biomarkers with advanced analytics to enhance the accuracy of Alzheimer’s disease diagnosis and prognosis.
Prof. Dr. Joachim SchultzeProf. Dr. Joachim L. Schultze is a renowned expert in systems medicine and genomics, serving as the Founding Director and W3-Professor at the DZNE in Bonn, Germany. As the Director of the PRECISE Platform for Single Cell Genomics and Epigenomics, he leads groundbreaking research into neurodegenerative diseases, leveraging single-cell multi-omics to advance precision medicine. With a career spanning prestigious positions at Harvard Medical School and the University of Cologne, Prof. Schultze’s work bridges genomics, immunology, and clinical applications. His contributions to the field are recognized globally, evidenced by numerous high-impact publications and his leadership in initiatives like the German COVID-19 Omics Initiative (DeCOI).
Prof. Dr. David Bartrés-FazProf. Dr. David Bartrés-Faz is a full professor in Psychology at the University of Barcelona, where he leads the Brain Health and Neuromodulation group. His research focuses on neuropsychological and behavioral patterns related to the aging brain and dementia.
Dr. Ruth StephenDr. Ruth Stephen is a postdoctoral researcher at the Karolinska Institutet in Stockholm, Sweden, working within the Nordic Brain Network. Her research interests include profiling individuals at risk of dementia based on brain and clinical characteristics, and identifying appropriate intervention strategies.
Dr. Florencia IulitaDr. Florencia Iulita leads the Medical Strategy and Operations at Altoida in Barcelona, a company dedicated to developing digital solutions for cognitive function monitoring. Altoida is an associated partner in the ADIS project, utilizing a tablet-based app to digitally assess cognitive function across different disease stages.
Dr. Jean-Marc van GyseghemDr. Jean-Marc van Gyseghem is a lawyer and director of the research center for “Information, Law and Society (CRIDS)” at the University of Namur. His expertise lies in data protection of medical data, and he is involved in several EU projects including DIGIPD, CERTAINTY, and AIPD.
Prof. Dr. Florian WiesingerProf. Dr. Florian Wiesinger is a Principal Scientist at GE Healthcare and a visiting professor at King’s College London. His research primarily focuses on medical imaging, contributing to advancements in the field of data science within healthcare.
Dr. Matt ClementDr. Matt Clement is the Director of Partnership & Scientific Strategy at Gates Ventures in New York, the personal service company of Bill Gates. He specializes in health technology and pharmaceutical development, with a particular focus on Alzheimer’s Disease.
Dr. Niranjan BoseDr. Niranjan Bose is the Managing Director of Health & Life Sciences at Gates Ventures. He serves as the Science Advisor to Bill Gates and oversees a portfolio of philanthropic investments in Global Health, Alzheimer’s Disease, and US Healthcare.
Prof. Dr. Dalia DawoudProf. Dr. Dalia Dawoud is an Associate Director at NICE, with over 20 years of experience as a health economist and researcher. Her work focuses on advancing health technology assessment (HTA) and clinical guideline development methods. She leads the NICE HTA Innovation Laboratory and oversees a portfolio of European Commission funded projects.
Prof. Dr. Xenia KobelevaProf. Dr. Xenia Kobeleva is an Assistant Professor and research group leader of the “Computational Neurology” group at Ruhr University of Bochum. As consultant neurologist and neuroscientist, she employs computational modeling to mechanistically describe effects of neurodegenerative diseases on structure and function. Based on these findings, she uncovers and experimentally validates new treatment strategies.
Dr. Gaby MarquardtDr. Gaby Marquardt heads the Center for Innovation in Diagnostics at Siemens Healthineers in Erlangen. She and her team focus on developing technologies and applications for workflows, assays, automation, and integrated systems across various disease areas, including Alzheimer’s Disease.
Dr. Anna-Katharine BremPD Dr. Anna-Katharine Brem is a senior researcher at both the University of Bern and King’s College London and has a background in neuropsychology. She plays a key role in the IHI project PREDICTOM, leading the digital biomarkers research stream and overall publication strategy while contributing significantly to clinical trial design and public engagement initiatives. She is moreover active in the IMI-project EPND, where she is responsible for “Best Practices in Digital Biomarkers” and significantly contributed to the IMI-project RADAR-AD.
Prof. Dr. Holger Fröhlich
Holger Fröhlich’s focus is on the development and application of data science (specificallyAI/ML) methods in biomedicine, with focus on early drug discovery, precision medicine and clinical trials. In this context, Holger Fröhlich has developed over the last 20 years a broad spectrum of data science approaches, including techniques for multi-modal data integration, (generative) time series modeling, hybrid AI approaches (ODE/NN combinations, Graph Neural Networks) and causal machine learning. He is author and co-author of more than 170 scientific publications. He has been coordinator of three EU projects (JNPD ADIS, ERA PerMed DIGIPD, AIPD), and partner in multiple further national and international research consortia as well as industry collaborations. Furthermore, he is scientific advisory board member of the international AI graduate school HIDSS4Health of the Helmholtz society.
Dr. Stefan Kirsch
Dr. Stefan Kirsch is a Principal Scientist at the Fraunhofer Institute for Toxicology and Medicine (ITEM), Division of Personalized Tumor Therapy. His expertise lies in the development and automation of innovative and robust single cell technologies for translational research across different disease areas.
Kuti Baruch, Ph.D.
Dr. Kuti Baruch is the VP of Research and Development at ImmunoBrain, a biopharmaceutical company developing immunotherapies for neurological disorders by targeting the peripheral immune system. At ImmunoBrain, his main focus has been the preclinical development of IBC-Ab002, a fully human anti-PD-L1 antibody designed to modulate the PD-1/PD-L1 immune checkpoint pathway for Alzheimer’s disease therapy. Dr. Baruch holds an M.Sc. in Medical Science from Tel Aviv University and a Ph.D. in Neurobiology from the Weizmann Institute of Science, Israel.
Soraya Moradi-Bachiller
Soraya is a biochemist by training specialised in Alzheimer’s disease and the biology of aging. She is Public Involvement Officer at Alzheimer Europe where she organises the involvement of members of the public in various research projects. Her work focuses on ensuring that the views and priorities of the people affected by the condition under study, and also that of their supporters and carers, are duly reflected in such projects.
Dr. Raquel Sanchez-Valle
Raquel Sanchez-Valle is a Senior Consultant neurologist at the Hospital Clínic de Barcelona (Spain), group leader of the Alzheimer’s disease and other cognitive disorders group at the FCRB-IDIBAPS and Associate professor at the University of Barcelona. Her main research lines are the characterization of preclinical and early phases of genetic dementias (ADAD, gFTD, gPrD) and the study of diagnosis and prognosis biomarkers in neurodegenerative dementias. She is a site PI in the ADIS project.
Dr. Neus Falgàs, MD, PhD
Dr. Neus Falgàs, MD, PhD is a neurologist specializing in Alzheimer’s disease and related dementias at Hospital Clínic de Barcelona. She completed a two-year postdoctoral fellowship at the University of California, San Francisco (UCSF), where she investigated sleep alterations in neurodegenerative diseases. Her research focuses on understanding neurobiological changes underlying sleep-wake disturbances in dementia, with a particular interest in noradrenergic system degeneration, especially in the locus coeruleus.
Sophia Krix
Sophia Krix is a PhD candidate in Computational Life Sciences at the Fraunhofer SCAI and the University of Bonn, Germany. Her work encompasses a wide range of Data Science and Artificial Intelligence applications within the biomedical field. Specifically, Sophia has focused on employing machine learning techniques to study sleep behavior in Alzheimer’s disease and has experience analyzing single-cell RNA sequencing data with modern machine learning methods. Sophia plays an integral role in the data science analysis of the ADIS project, and she is also knowledgeable in Graph Machine Learning, especially in its applications for drug development.